Continued treatment for cancer patients from earlier Roche studies
Continues Roche cancer medicines for people still on treatment from an earlier study.
Plain-language title generated from the registry record
Registry title: A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Key facts
- Where
- Bangkok and Chiang Mai, ThailandSee the 3 sites
- Phase
- Phase 3
Where in Thailand
- Siriraj HospitalBangkok, ThailandTaking people
- Chulalongkorn HospitalBangkok, ThailandNo longer taking part
- Maharaj Nakorn Chiangmai HospitalChiang Mai, ThailandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT05862285EU 2023-504263-16-00
- Record updated
- 6 November 2026
- Original description
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP[s]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.Read full original descriptionShow less
An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP[s]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.
Inclusion: Eligible for continuing Roche IMP-based therapy at the time of roll-over from the parent study, as per the parent study protocol OR; Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study protocol, with no access to commercially available comparator agent; First dose of study treatment in this extension study will be received within 7 days of the treatment interruption window allowed by the parent study; Continue to benefit from the Roche IMP-based therapy or comparator at the time of roll-over from the parent study as assessed by the investigator; Ability to comply with the extension study protocol, per Investigator's judgement.
Exclusion: Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this extension study; Concurrent participation in any therapeutic clinical trial (other than the parent study); Study treatment or comparator agent is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant; Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study; Permanent discontinuation of all study treatment(s) or comparator agent(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable); Ongoing SAE(s) that has not resolved to baseline level or Grade ≤1 from the parent study or during the time between the last treatment in the parent study and the first dose of study treatment in this extension study. Potential participants with an ongoing SAE that has not resolved to baseline level or Grade 1 may be enrolled at the investigator's discretion, provided the event is deemed clinically stable and the investigator documents that the potential clinical benefit outweighs the risk to the potential participant.